Liver Transplantation

IDN-6556 gets orphan drug designation

Published in Blood Weekly, October 23rd, 2003

Idun Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of IDN-6556 to treat patients undergoing liver transplantation and other solid organ transplantations.

IDN-6556 is a drug intended to protect liver cells (hepatocytes) from excessive programmed cell death, also known as apoptosis. Excessive apoptosis has been implicated in many different liver diseases and conditions. Idun believes that IDN-6556 will be beneficial in the treatment of the injury that occurs during liver transplantation procedures.

Orphan drug designation will apply to the treatment of patients with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2003-10-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry